Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
about
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia.Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI.
P2860
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Platelet thrombin receptor ant ...... nd clinical trial development.
@en
type
label
Platelet thrombin receptor ant ...... nd clinical trial development.
@en
prefLabel
Platelet thrombin receptor ant ...... nd clinical trial development.
@en
P2093
P2860
P356
P1433
P1476
Platelet thrombin receptor ant ...... nd clinical trial development.
@en
P2093
Dominick J Angiolillo
Fabiana Rollini
Francesco Franchi
Yongwhi Park
P2860
P304
P356
10.2217/FCA.15.50
P577
2015-09-25T00:00:00Z